Clinical Trial Update: Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing erlotinib monotherapy with docetaxel plus cisplatin as neoadjuvant therapy in stage IIIA non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Non-small Cell Lung Cancer(NSCLC) | Phase 2 | Status: UNKNOWN